EULARIS

WHY AN AI STRATEGIC BLUEPRINT IS THE VITAL FIRST STEP FOR SUCCESSFUL AI SOLUTION IMPLEMENTATION

By Dr. Andrée Bates,
CEO, Eularis



CONTENTS

THE IMPORTANCE OF AI IN PHARMA

The pharmaceutical industry is currently witnessing a transformative era with the advent of artificial intelligence (AI). With its remarkable potential to revolutionize drug discovery, development, and delivery, AI is rapidly emerging as a powerful tool that promises to reshape the way medicines are developed and brought to patients.

The integration of AI technologies such as machine learning (including generative AI), natural language processing, and deep learning can help pharmaceutical companies to extract insights from vast amounts of data, identify new drug targets, and design more efficient clinical trials.

The impact of AI in the pharmaceutical industry cannot be overstated, as demonstrated by the escalating number of AI-driven projects being undertaken. However, a significant number of these initiatives encounter obstacles and fail to progress beyond the pilot stage. It is often humorously remarked that the pharmaceutical industry has more pilots than the airline industry.

One of the primary reasons behind these challenges lies in the approach taken by many pharmaceutical organizations when implementing AI. Often, AI is treated as an ad hoc pilot, or impressive AI tools are acquired without a thorough assessment of their alignment with the company's strategic objectives and the goals of individual business units. Consequently, substantial financial resources are squandered on unsuccessful pilots and shiny new AI tools that fail to address critical organizational needs. This results in ineffectiveness and a lack of alignment with strategic goals.

To ensure the successful implementation of AI in the pharmaceutical industry, a clear and comprehensive strategic blueprint is indispensable. It examines corporate and business unit strategies, stakeholder needs, ecosystem impacts, and relevant technologies. By identifying optimal AI solutions and assessing them against various criteria, the strategic blueprint enhances operational efficiency, facilitates revenue generation, and ensures alignment with overarching strategic objectives.

This whitepaper shed light on the critical significance of a strategic blueprint in ensuring the successful implementation of AI in the pharmaceutical industry and provides insights on why to develop and execute such a blueprint.

> *To ensure the successful implementation of AI in the pharmaceutical industry, a clear and comprehensive strategic blueprint is indispensable.*

THE CRITICAL NEED FOR A STRATEGIC AI BLUEPRINT

The complexity of the pharma industry, coupled with the risks associated with AI implementation, underscores the need for a strategic blueprint. With a plethora of data pouring in from diverse sources like clinical trials, electronic health records, and genomic data, identifying relevant information for specific tasks can be challenging. The high dimensionality and heterogeneity of pharma data further exacerbate this challenge.

AI techniques such as machine learning and natural language processing can help manage the complexity of data and extract insights from it.

However, these techniques require a well-defined strategy to apply them appropriately.

1. **Alignment with Organizational Strategy:** A strategic blueprint ensures that the AI initiatives align with the overall organizational strategy. This alignment is critical for ensuring that the AI initiatives contribute to the overall goals and objectives of the company, avoiding isolated and disconnected efforts. By having a clear strategic blueprint, organizations can avoid the pitfalls of "technology for technology's sake" and focus on driving tangible value and impactful outcomes

2. **Stakeholder Alignment and Understanding their Pain Points:** Successful AI implementation hinges on understanding the pain points of relevant stakeholders. Depending on the company, these stakeholders could be commercial teams, medical affairs, market access, regulatory, R&D, or the organization as a whole. A strategic blueprint provides a transparent roadmap for strategic AI initiatives, enabling alignment with stakeholder needs. This alignment ensures that AI initiatives meet the strategic objectives of the respective teams, fostering a cohesive and collaborative environment.

The complexity of the pharma industry, coupled with the risks associated with AI implementation, underscores the need for a strategic blueprint.

3. **Mitigation of Risks and Challenges:** Implementing AI in the pharma industry comes with inherent risks and challenges. These include data quality issues, lack of standardization, regulatory compliance, and ethical considerations. A strategic blueprint identifies these risks and challenges proactively, allowing organizations to develop mitigation strategies. By addressing these concerns early on, organizations can mitigate potential roadblocks, minimize delays, and pave the way for successful AI initiatives.

4. **Maximizing project success:** An alarming number of AI projects in pharma fail to deliver the desired outcomes. Gartner reported that only 15% of AI projects succeed. That is 85% that fail which is in line with what McKinsey reported. The reason for this is that the majority were done without a strategic AI blueprint in place. Many projects are conducted in an ad hoc and experimental manner, lacking the necessary strategic alignment. This leads to suboptimal impact and disappointing results. By adhering to a comprehensive strategic blueprint, pharma organizations can increase the chances of project success by planning for strategic alignment from the outset.

5. **Efficient Resource Allocation:** Implementing AI initiatives in the pharma industry demands significant investments of time, capital, and talent. A strategic blueprint provides a systematic analysis of resource requirements for various AI initiatives, aiding in prioritization and strategic fit assessment. By optimizing resource allocation, organizations can make informed decisions about where to invest their AI-related resources, ensuring maximum return on investment (ROI).

Implementing AI in the pharma industry comes with inherent risks and challenges.

The potential benefits of artificial intelligence (AI) in the pharmaceutical industry are immense. McKinsey's research highlights that AI has the potential to reduce drug development timelines by 25-30%, leading to faster delivery of innovative treatments to patients.

Moreover, AI can help cut clinical trial costs by up to 75% by enabling more efficient patient recruitment, optimizing trial design, and facilitating data analysis. AI can also write Clinical Study Reports that are 90% complete in less than an hour saving 6 weeks of team time. Moreover, the application of AI-driven predictive models and insights can enhance the success rate of clinical trials by up to 50%.

The potential is not limited to these areas. Eularis implements AI throughout the pharma value chain resulting in substantial productivity improvements. In the field of medical affairs, AI has enabled productivity gains of around 100% by significantly reducing the time spent on literature monitoring (up to 92%). Furthermore, AI can automate Global Value Dossiers, ensuring they are continuously updated to stay abreast of the latest scientific literature.

Pharmacovigilance is another area that benefits stronger from AI. In addition, we have automated many regulatory processes such as changes in guidance documents and more. AI applied in market access results in stronger value pricing, faster reimbursement, and automated insights.

Furthermore, AI in sales and marketing offers tangible benefits. For example, AI-driven landscape assessments and go-to-market strategies have led to measurable revenue generation increases of 10-37%. AI enables precise targeting of healthcare professionals (HCPs), facilitates the identification of patients with rare diseases, and assists in the discovery of emerging Key Opinion Leaders (KOLs), among other valuable applications.

Some of the sales and marketing applications can be found in this white paper.

https://www.linkedin.com/pulse/how-embed-artificial-intelligence-pharma-sales-marketing-bates/

...AI throughout the pharma value chain resulting in substantial productivity improvements...

Despite the immense potential, many pharmaceutical companies face challenges when it comes to identifying the AI projects that will effectively provide a strong impact and then scaling AI initiatives beyond pilot projects. According to the McKinsey report, a mere 13% of AI projects in healthcare advance beyond the testing phase, highlighting the necessity for strategic guidance and implementation frameworks. A survey conducted by Deloitte further unveils that merely 13% of pharmaceutical companies presently possess a comprehensive AI strategy, with a meager 29% allocating a dedicated budget for AI initiatives.

These statistics underscore the critical need for an AI strategic blueprint that not only guides AI implementation but also ensures scalability and long-term success. An AI blueprint offers a structured approach to identify the most suitable AI applications, allocate resources effectively, and align AI initiatives with corporate goals. It facilitates the integration of AI into various aspects of the pharmaceutical value chain, including research and development, manufacturing, supply chain management, marketing, and patient engagement.

These statistics underscore the critical need for an AI strategic blueprint that not only guides AI implementation but also ensures scalability and long-term success.

THE BENEFITS OF A STRATEGIC AI BLUEPRINT

Implementing artificial intelligence (AI) in the pharmaceutical industry can offer significant benefits, such as improving decision-making, increasing efficiency, generating significantly greater revenue, reducing costs, increasing innovation, improving the HCP experience, and ultimately improving patient outcomes.

However, realizing these benefits requires a well-designed AI blueprint.

1. Alignment with Corporate Goals: By defining a clear strategy for AI implementation, pharmaceutical companies can ensure that their AI initiatives are focused on addressing the most important business challenges and opportunities.

One pressing challenge faced by many pharmaceutical companies is the patent cliff, where the expiration of patents on existing products can lead to a significant revenue decline. To mitigate this impact, companies must prioritize the efficient introduction of new drugs to the market and maximize revenues before patent expiration. Leveraging AI in this context becomes crucial. An AI strategic blueprint provides a strategic framework to identify areas where AI can be applied strategically.

For example, AI can analyze vast amounts of data to accelerate drug development timelines, identifying promising drug candidates and predicting their safety and efficacy. Moreover, AI enables real-time data analysis from clinical trials, empowering companies to make informed decisions about optimal patient cohorts and the development and commercialization strategies of their drugs.

Implementing artificial intelligence (AI) in the pharmaceutical industry can offer significant benefits, such as improving decision-making, increasing efficiency, generating significantly greater revenue, reducing costs, increasing innovation, improving the HCP experience, and ultimately improving patient outcomes.

2. Real-world impact: Ensuring that AI initiatives have a tangible business impact is a critical benefit of having an AI blueprint. Pharmaceutical companies invest significant resources into developing and implementing AI initiatives, and it is essential to ensure that these initiatives have a real-world impact on the business.

One way to ensure that AI initiatives have a tangible business impact is to identify where the corporate and business unit goals can leverage AI effectively to achieve them, as well as define clear objectives for each initiative, how to achieve those objectives leveraging AI as an enabler and to measure the outcomes against these objectives.

For example, a pharmaceutical company may implement an AI initiative to streamline the drug development process. The objective of the initiative may be to reduce the time it takes to bring a new drug to market by 30%. By defining clear objectives and measuring outcomes against these objectives, the company can ensure that the AI initiative has a tangible impact on the business.

There are several examples of pharmaceutical companies that have successfully implemented AI initiatives that have had a tangible business impact.

For instance, Pfizer implemented an AI system utilizing machine learning algorithms to analyze clinical trial data. This system enabled Pfizer to identify biomarkers that predict patient response to specific drugs, leading to more targeted therapies and cost and time savings in clinical trials.

Likewise, Novartis implemented an AI system powered by natural language processing algorithms to analyze patient data and identify adverse drug events. This proactive approach enabled Novartis to detect potential safety issues earlier in the drug development process, reducing the risk of trial failures and associated costs.
By ensuring that AI initiatives have a tangible business impact, pharmaceutical companies can realize significant benefits. A recent study by Accenture found that companies that invest in AI and other digital technologies could increase their revenue by up to 38% and their profitability by up to 45%. However, to unlock these benefits, it is essential to align AI initiatives with business goals, measure outcomes, and continually refine strategies based on data-driven insights.

One way to ensure that AI initiatives have a tangible business impact is to identify where the corporate and business unit goals can leverage AI effectively to achieve them.

3. Lower failure rate

Reducing the rate of AI projects failing to achieve their objectives is another critical benefit of having an AI strategic blueprint. Pharmaceutical companies invest a significant amount of time, money, and resources in AI projects. However, despite the potential benefits of AI, many projects fail to deliver the expected results. According to a survey by Gartner, up to 85% of AI projects fail to deliver their intended business benefits and only 15% of AI projects could be defined as a success.

An AI strategic blueprint ensures that AI projects are aligned with the overarching business goals of the pharmaceutical company. By clearly defining the objectives for each AI project, companies can establish a focused direction and avoid embarking on projects that lack strategic relevance. This alignment ensures that AI initiatives are purposeful, measurable, and contribute to the desired business outcomes.

Pharmaceutical companies that have embraced an AI strategic blueprint have experienced remarkable success. Merck, for instance, implemented an AI project utilizing machine learning algorithms to analyze chemical structures and predict viable drug candidates for clinical trials. This project successfully reduced the time and cost of drug discovery, resulting in the identification of several promising compounds.

Similarly, Sanofi implemented an AI project leveraging machine learning algorithms to analyze patient data and identify potential new drug targets. The project accelerated drug discovery efforts and yielded several successful drug candidates. These examples demonstrate how an AI strategic blueprint can lead to tangible success in pharmaceutical research and development.

By reducing the failure rate of AI projects, pharmaceutical companies can save significant resources and minimize the risk of costly setbacks. According to Deloitte, failed AI projects can result in substantial financial losses ranging from tens of thousands to millions of dollars. By leveraging an AI strategic blueprint, companies can minimize the risk of project failures and allocate resources more efficiently, ensuring optimal utilization of time, money, and talent.

An AI strategic blueprint ensures that AI projects are aligned with the overarching business goals of the pharmaceutical company.

4. Effective scalability

Ensuring that AI pilot projects are able to scale effectively is another important benefit of having an AI blueprint. Many pharmaceutical companies start with pilot projects to test the viability of AI solutions before implementing them across the organization. However, the challenge lies in scaling these pilot projects effectively to realize the full benefits of AI.

Having an AI strategic blueprint serves as a roadmap for the development and implementation of AI pilot projects. It outlines clear guidelines for testing, evaluation, and identification of successful projects that have the potential for effective scalability. This strategic approach enables pharmaceutical companies to leverage valuable insights gained from pilot projects and seamlessly expand AI initiatives throughout the organization.

There are several examples of pharmaceutical companies that have successfully scaled their AI pilot projects by implementing an AI blueprint. For example, Pfizer implemented an AI blueprint that included a roadmap for the development and scaling of AI initiatives. The blueprint helped the company to identify successful pilot projects and develop strategies for scaling them effectively.

Similarly, Sanofi implemented an AI blueprint that included comprehensive guidelines for testing and evaluation of pilot projects. Through the blueprint's strategic approach, Sanofi successfully identified promising pilot projects and efficiently scaled them across the organization. This scalable implementation resulted in enhanced productivity, streamlined processes, and optimized business outcomes.

Having an AI strategic blueprint serves as a roadmap for the development and implementation of AI pilot projects.

5. Proactive Approach

Traditionally, pharmaceutical companies have relied on reactive approaches to address business challenges, waiting until a problem arises before taking action. However, in today's rapidly changing business environment, this approach is no longer sufficient.

An AI blueprint can help pharmaceutical companies to take a more proactive approach to emerging business challenges and opportunities. By providing a roadmap for the development and implementation of AI initiatives, the blueprint enables companies to identify potential challenges and opportunities and develop strategies to address them proactively.

One exemplary pharmaceutical company that has embraced this proactive approach is GlaxoSmithKline (GSK). GSK has integrated an AI-based system into its operations, which accurately predicts drug compound toxicity. This implementation has not only saved millions of dollars in development costs but has also reduced the risk of drug failures. By staying ahead of the curve in drug development, GSK has fortified its position as a leading pharmaceutical company.

Novartis presents another compelling example of the benefits of a proactive approach. The company has harnessed the power of an AI-powered drug discovery platform, enabling faster and more efficient identification of new drug candidates. By proactively embracing this technology, Novartis has maintained its leadership in the pharmaceutical industry and outpaced its competitors in drug discovery endeavors.

By adopting a proactive approach and integrating AI solutions, pharmaceutical companies can unlock significant benefits. They can uncover untapped opportunities, streamline processes, reduce costs, and enhance overall business performance. Furthermore, by leveraging AI to predict and identify potential issues, they can preemptively mitigate risks before they escalate into significant challenges.

An AI blueprint can help pharmaceutical companies to take a more proactive approach to emerging business challenges and opportunities.

6. Operational Efficiency

Optimizing business processes and operations through AI-driven automation and decision-making is another key benefit of having an AI blueprint in place for pharmaceutical companies. By harnessing the power of AI to automate tasks and enhance decision-making, companies can streamline their processes, lower costs, and elevate overall business performance.

Pfizer serves as a prime example of a pharmaceutical company that has effectively utilized AI to optimize its operations. By implementing an AI-driven digital assistant, Pfizer has automated mundane tasks such as data entry and document processing. This strategic adoption of AI has streamlined operations, reduced costs, and significantly enhanced the accuracy and efficiency of critical business processes.

In addition to automating routine tasks, AI can also be used to optimize decision-making processes. For example, AI algorithms can analyze data from clinical trials and other sources to identify patterns and insights that may not be apparent to human analysts. This can help pharmaceutical companies to make more informed decisions about drug development, clinical trials, and other business operations.

Another area where AI can be used to optimize business processes and operations is supply chain management. By using AI algorithms to analyze data on demand and supply patterns, pharmaceutical companies can optimize inventory management and reduce waste. This proactive approach yields significant cost savings and bolsters operational efficiency across the supply chain.

This strategic adoption of AI has streamlined operations, reduced costs, and significantly enhanced the accuracy and efficiency of critical business processes.

7. Enhanced Customer Experience

Delivering exceptional customer experiences and tailored services are paramount for pharmaceutical companies, and an AI strategic blueprint can be instrumental in achieving this goal. By harnessing the power of AI to analyze customer data, companies can gain valuable insights into customer preferences, needs, and behaviors. This enables them to provide personalized and relevant products and services, elevating the overall customer experience.

One example of a pharmaceutical company that has successfully leveraged AI to improve customer experience is Novartis. The company has implemented an AI-powered chatbot called "Ella" that provides personalized support and information to patients with multiple sclerosis. The chatbot uses natural language processing and machine learning algorithms to understand patients' questions and provide relevant information and support. This has helped Novartis to improve the quality and consistency of customer interactions and services and enhance the overall patient experience.

Merck presents another compelling case by implementing a virtual assistant known as MIA (Merck Intelligent Assistant). MIA caters to the specific needs and preferences of healthcare professionals, providing personalized support and guidance. Through natural language processing and machine learning, MIA offers tailored recommendations and insights based on individual analysis. This personalized approach empowers healthcare professionals and contributes to a heightened customer experience.

In addition to chatbots, AI can also be used to personalize marketing and sales communications. For example, AI algorithms can analyze customer data to identify patterns and insights that can inform more effective marketing and sales strategies. This can lead to more personalized and relevant communications with customers, and ultimately, improve the overall customer experience.

AI also plays a pivotal role in expediting and improving diagnosis and treatment processes. By scrutinizing vast amounts of patient data, AI algorithms can identify patterns and insights that may that may not be apparent to human doctors. This capability leads to swifter and more accurate diagnoses, ultimately resulting in improved patient outcomes.

One example of a pharmaceutical company that has successfully leveraged AI to improve customer experience is Novartis.

8. Cost Savings

By leveraging AI technology, companies can identify cost-saving opportunities across different operations, including supply chain, manufacturing, and clinical trials. AI algorithms can analyze data from various sources to identify inefficiencies and areas of improvement, enabling pharmaceutical companies to streamline their processes and minimize waste.

For example, a comprehensive study conducted by McKinsey & Company revealed that AI-powered predictive maintenance techniques can reduce maintenance costs by up to 25% while increasing machine uptime by as much as 20%. Additionally, AI-enabled inventory management systems can help companies avoid the pitfalls of overstocking or understocking, resulting in significant cost savings.

Moreover, AI technology can help companies optimize their resource management by predicting demand, identifying areas of over or under-staffing, and improving resource allocation.

According to a report by Accenture, by 2035, AI could potentially save the pharmaceutical industry up to $100 billion annually in the areas of R&D, manufacturing, and supply chain management.

According to a report by Accenture, by 2035, AI could potentially save the pharmaceutical industry up to $100 billion annually in the areas of R&D, manufacturing, and supply chain management.

9. Revenue Increases

In the fast-paced pharmaceutical industry, an AI strategic blueprint can be a game-changer, driving revenue growth and uncovering new business opportunities. By harnessing the power of AI-driven data analysis and customer insights, pharmaceutical companies can identify untapped revenue streams and capitalize on emerging trends.

AI technology plays a vital role in identifying market gaps and areas for drug development. Through sophisticated analysis of patient needs, healthcare trends, and other critical factors, AI can pinpoint opportunities for developing new drugs or repurposing existing ones for novel applications. This strategic approach enables companies to stay ahead of the curve and seize lucrative market opportunities.

Marketing and sales strategies can also be greatly enhanced through AI. By leveraging AI to analyze customer data and behavior, pharmaceutical companies can personalize their marketing messages and target their efforts with precision. This tailored approach resonates with customers, leading to increased sales and revenue growth.

Furthermore, AI empowers companies to optimize pricing strategies and revenue management. By analyzing market data and demand trends, AI algorithms provide valuable insights that enable companies to set competitive prices aligned with market demand. This data-driven approach ensures maximum revenue generation and a stronger market position.

Marketing and sales strategies can also be greatly enhanced through AI.

10. Staff Satisfaction and Retention

By empowering employees with AI-driven tools and insights, they are able to perform their job roles more effectively and efficiently. This can lead to increased job satisfaction and motivation, as well as a sense of ownership and investment in the company's success.

AI-enabled tools play a pivotal role in automating routine tasks and delivering real-time insights. By automating repetitive and mundane activities, employees are freed up to focus on more complex and intellectually stimulating work. This not only enhances their job satisfaction but also enables them to contribute more meaningfully to the company's objectives. With access to real-time insights, employees can make informed decisions and take proactive measures, resulting in improved overall performance.

Moreover, AI technology supports the identification of areas for employee performance enhancement. By leveraging AI algorithms, companies can analyze individual performance data and provide personalized training and development opportunities tailored to each employee's needs. This customized approach fosters continuous growth, enabling employees to upskill and excel in their roles.

Research has consistently shown that increased job satisfaction and engagement have a direct impact on reducing attrition rates. By investing in the satisfaction and development of their workforce, companies can mitigate the costly process of recruiting and training new employees. In fact, a study conducted by Gallup revealed that companies with highly engaged employees experienced a remarkably 21% higher profitability compared to those with low engagement levels.

By empowering employees with AI-driven tools and insights, they are able to perform their job roles more effectively and efficiently.

11. Patient Outcomes

AI-powered healthcare solutions have revolutionized the way healthcare professionals analyze vast amounts of data, enabling them to make accurate diagnoses and informed treatment decisions. By leveraging AI technology, healthcare providers can unlock invaluable insights from patient records, medical histories, and clinical trials.

For instance, IBM Watson for Oncology uses AI to analyze a patient's medical history and genetic data to provide oncologists with personalized treatment recommendations. A study conducted by Memorial Sloan Kettering Cancer Center found that Watson for Oncology's recommendations aligned with those of oncologists in 96% of breast cancer cases.

Moreover, AI can aid in early detection and prevention of diseases. For example, deep learning algorithms can analyze medical images, such as X-rays and MRI scans, to detect abnormalities that might be missed by human radiologists. The use of AI in detecting diabetic retinopathy has shown promising results, with Google's AI-based screening tool achieving a 94% accuracy rate in detecting the disease.

By improving patient outcomes, AI-driven healthcare can lead to reduced hospital readmissions, decreased healthcare costs, and improved patient satisfaction.

AI-powered healthcare solutions have revolutionized the way healthcare professionals analyze vast amounts of data, enabling them to make accurate diagnoses andinformed treatment decisions.

12. Competitive Advantage

By using AI to automate and optimize various processes, companies can differentiate themselves from competitors and become more innovative and efficient in their approach to drug development, manufacturing, and distribution. For example, AI-powered drug discovery platforms can help identify new and more effective treatments, giving companies an edge in the market.

AI can also help companies improve their supply chain management, reducing costs and increasing efficiency. This can lead to better delivery times, faster product development, and ultimately, greater customer satisfaction. Additionally, AI can enable pharmaceutical companies to better understand their customers' needs and preferences, allowing them to tailor their products and services to meet those needs.

One example of a company that has successfully used AI to gain a competitive advantage is Novartis. The company has developed an AI-based platform called the Novartis AI Innovation Lab, which aims to accelerate drug discovery and development by using AI and machine learning algorithms to analyze large amounts of data. This has allowed Novartis to identify new drug targets and develop more effective treatments for various diseases.

By using AI to automate and optimize various processes, companies can differentiate themselves from competitors and become more innovative and efficient in their approach to drug development, manufacturing, and distribution.

THE RISKS OF IMPLEMENTING AI SOLUTIONS WITHOUT A STRATEGIC AI BLUEPRINT

The implementation of artificial intelligence (AI) solutions in the pharmaceutical industry is gaining momentum due to its ability to drive efficiency, accuracy, and innovation in various business operations. However, implementing AI solutions without a strategic AI blueprint can lead to several risks and challenges that can jeopardize the organization's success and reputation.

Some of these risks include:

1. Implementing projects that do not align with strategic goals: One of the risks of implementing AI solutions without a strategic blueprint is the possibility of implementing projects that do not align with the company's strategic goals. This can lead to wasted investment and resources and lost opportunities for the company. Without a clear plan and direction for AI initiatives, companies may pursue projects that are not relevant or beneficial to their overall business strategy and waste huge amounts of money and time.

To mitigate this risk, it is imperative to gain a comprehensive understanding of the company's strategic goals and how AI can be effectively harnessed to support them. This necessitates a thorough analysis of the organization's strategic needs and an evaluation of the potential impact of AI initiatives on various facets of the business. By aligning AI projects with strategic goals, companies can optimize the outcomes of their investments and ensure efficient resource allocation.

However, implementing AI solutions without a strategic AI blueprint can lead to several risks and challenges that can jeopardize the organization's success and reputation.

2. Wasting resources on ineffective projects: Implementing AI solutions without a well-defined blueprint can result in significant resource wastage on ineffective projects that fail to generate value for the business. This squandering of financial resources can hinder progress and impede the achievement of desired outcomes. While AI holds great potential across the pharmaceutical value chain, a lack of clarity regarding the specific problems to be addressed and the intended goals can lead to aimless and unfocused AI initiatives.

According to a study conducted by Gartner, nearly 85% of AI projects fail to deliver the anticipated benefits. Factors contributing to this failure include ambiguous objectives, inadequate data quality, and a lack of skilled personnel. This emphasizes the criticality of establishing a clear AI blueprint prior to implementing any AI solutions.

To mitigate this risk, companies should undertake a comprehensive analysis encompassing factors such as strategic fit, likelihood of success, cost-benefit considerations, and more. This assessment helps evaluate the potential benefits and risks associated with the AI project before committing resources. Furthermore, it is essential to ensure that the project aligns with the company's strategic goals and possesses well-defined objectives and measurable metrics for success.

This emphasizes the criticality of establishing a clear AI blueprint prior to implementing any AI solutions.

3. Inability to scale pilot AI projects effectively

One of the biggest risks of implementing AI solutions without a proper blueprint is the inability to scale pilot projects effectively. Many companies start by testing AI solutions on a small scale, with a limited budget and a few team members. However, if these pilot projects are successful, the company may want to expand its implementation to a larger scale. If the company does not have a solid plan in place for scaling up, the project can quickly become too complex and difficult to manage.

One example of the challenges of scaling up AI projects comes from a study published in the Journal of Medical Systems found that many healthcare organizations struggle to scale AI initiatives beyond pilot projects. The study cites factors such as a lack of infrastructure, limited budget and resources, and difficulty integrating AI with existing systems as common barriers to scaling up.

Without a proper strategic blueprint, a company may also struggle to ensure that its AI solutions are scalable across different regions and markets. Each market may have unique regulatory requirements, cultural differences, and infrastructure challenges that need to be addressed. Failure to account for these factors can result in a lack of adoption or even outright failure of the project.

To avoid this risk, it is essential to incorporate scalability considerations into the AI blueprint from the outset. This ensures that the pilot projects are designed to accommodate the increasing data and complexity as the system scales, resulting in a smoother and more effective scaling process.

One of the biggest risks of implementing AI solutions without a proper blueprint is the inability to scale pilot projects effectively.

4. Failure to foresee strategic risks and implications of AI solutions

When implementing AI solutions without a proper blueprint, it's easy to overlook the strategic risks and implications of these technologies. For example, the use of AI in healthcare can bring significant benefits, such as increased efficiency and accuracy in diagnosis and treatment. However, it also raises concerns about data privacy, security, and ethical considerations related to the use of patient data.

One notable example of the potential risks of AI in healthcare is the case of Google's DeepMind and the Royal Free Hospital in London. In 2016, DeepMind was granted access to the personal data of 1.6 million patients without their explicit consent for a kidney monitoring app. The UK Information Commissioner's Office found that the Royal Free had failed to comply with the Data Protection Act, highlighting the importance of ethical considerations and regulatory compliance when implementing AI solutions.

Another example is the use of biased data in AI algorithms, which can perpetuate systemic inequalities and discrimination. For instance, a study by the American Medical Association found that some popular medical algorithms used to predict healthcare needs were less accurate for Black patients than for white patients, potentially resulting in misdiagnosis or inadequate care. Biases in data can be amplified if not dealt with before starting.

Without a proper blueprint for AI implementation, companies may fail to identify and address these strategic risks, leading to negative consequences for both the company and its stakeholders.

When implementing AI solutions without a proper blueprint, it's easy to overlook the strategic risks and implications of these technologies.

5. Data privacy and security risks

The implementation of AI solutions without a well-defined blueprint raises significant concerns regarding data privacy and security within the pharmaceutical industry. Pharmaceutical companies handle vast quantities of sensitive data, encompassing patient information, clinical trial outcomes, and proprietary research data. The potential consequences of this information falling into the wrong hands are severe, including legal and financial ramifications, damage to the company's reputation, and potential harm to patients.

Examples of data breaches and privacy violations in the pharmaceutical industry are not uncommon. In 2019, an unsecured server containing the personal data of over 8 million patients was discovered, which included information such as their names, addresses, dates of birth, and medical histories.

In 2020, a major pharmaceutical company disclosed that it had experienced a data breach that potentially exposed the personal and medical information of 300,000 patients.

Another notable incident took place in 2015 when Anthem Inc., one of the largest health insurers in the United States, fell victim to a cyberattack, leading to the exposure of personal information for 78.8 million individuals. This breach resulted in the company incurring over $115 million in settlement fees and associated costs.

AI solutions that utilize large amounts of sensitive data can also be vulnerable to cyber attacks, which can be costly and disruptive. To mitigate these risks, pharmaceutical companies must implement rigorous data protection and security protocols and ensure that they are compliant with data privacy regulations such as the General Data Protection Regulation (GDPR) and the Health Insurance Portability and Accountability Act (HIPAA).

Furthermore, it is imperative for pharmaceutical companies to uphold patient privacy and confidentiality when implementing AI solutions. This necessitates obtaining appropriate informed consent for the utilization of patient data and safeguarding patient anonymity throughout any data analysis processes. Failing to adhere to these principles can result in significant legal and reputational repercussions for the organization.

In 2020, a major pharmaceutical company disclosed that it had experienced a data breach that potentially exposed the personal and medical information of 300,000 patients.

6. Ethical Considerations and Implications

One of the main concerns is the potential for bias in AI algorithms, which could result in discrimination against certain groups of patients. For example, a study found that an algorithm used by some hospitals to predict which patients would need extra care prioritized white patients over black patients.

Another ethical concern is the potential for AI to be used to make life-or-death decisions without sufficient human oversight. While AI may be able to process large amounts of data and identify potential health issues more quickly than humans, it is still not capable of making ethical judgments or taking into account individual patient values and preferences.

Moreover, there are concerns about transparency and accountability, as AI systems are often complex and difficult to interpret, making it challenging to understand how decisions are being made.

Additionally, the use of AI in healthcare raises concerns about the security and privacy of patient data. AI algorithms rely on large amounts of data to learn and make predictions, but this data must be protected to ensure data privacy. As more healthcare data is collected and analyzed, there is an increased risk of data breaches and cyber-attacks.

One example of the ethical implications of AI in healthcare is the use of facial recognition technology to identify patients. While this technology may make it easier for healthcare providers to access patient data and provide more personalized care, it also raises concerns about privacy and potential misuse of the data.

Moreover, there are concerns about transparency and accountability, as AI systems are often complex and difficult to interpret, making it challenging to understand how decisions are being made.

7. Regulatory compliance issues

Implementing AI solutions without a proper blueprint can also result in regulatory compliance issues for companies. The use of AI in the healthcare industry, including pharma, is subject to numerous regulatory requirements and guidelines. Failure to comply with these regulations can lead to legal and financial repercussions for the company.

For example, in the United States, the FDA has issued guidelines for the development and use of AI in medical devices. Failure to adhere to these guidelines can result in fines or even product recalls.

Furthermore, compliance with regulations such as the General Data Protection Regulation (GDPR) and the Health Insurance Portability and Accountability Act (HIPAA) is crucial for protecting patient data privacy. AI solutions that handle patient data must be designed with compliance in mind to avoid potential legal and financial consequences.

For instance, in 2019, Google was fined $1.7 billion by the European Union for violating antitrust laws with its advertising practices. The company's use of AI in advertising was deemed to have given it an unfair advantage over its competitors. This example shows how regulatory compliance issues can arise even for established companies like Google, emphasizing the importance of implementing AI solutions with compliance in mind from the outset. Pharma companies are subject to far stricter regulations than companies such as Google so it is imperative that we adhere to regulations compliantly.

For example, in the United States, the FDA has issued guidelines for the development and use of AI in medical devices. Failure to adhere to these guidelines can result in fines or even product recalls.

8. Unforeseen consequences and risks

The implementation of AI solutions without a blueprint can also lead to unforeseen consequences and risks. One of the major risks is the lack of transparency and interpretability of the algorithms used in AI systems, which can lead to unintended outcomes.

For example, in healthcare, if an AI system is trained on biased data, it could lead to incorrect diagnoses or treatment recommendations, resulting in harm to patients.

Another risk is the potential for AI systems to amplify existing inequalities. For instance, AI systems used in hiring or lending decisions may replicate existing biases and perpetuate discrimination against certain groups of people. This can have significant legal and reputational implications for organizations.

Additionally, there is a risk of over-reliance on AI systems, leading to a loss of human judgment and decision-making. This can be particularly problematic in critical domains such as healthcare, where decisions made by AI systems could have life-or-death consequences.

It is crucial to thoroughly evaluate and monitor the impact of AI solutions to identify and mitigate any unforeseen consequences and risks. This can be done by implementing ethical guidelines, involving diverse stakeholders in the development process, and regularly auditing AI systems to ensure they are aligned with organizational values and goals.

One of the major risks is the lack of transparency and interpretability of the algorithms used in AI systems, which can lead to unintended outcomes.

KEY ELEMENTS OF A STRATEGIC AI BLUEPRINT

A strategic AI blueprint is a comprehensive plan that outlines the objectives, strategies, and tactics for implementing AI solutions within an organization. A well-designed blueprint should take into account various factors such as the company's goals, the available data, resources, and the regulatory and ethical considerations surrounding AI use.

Some key elements of a strategic AI blueprint include

Understanding strategic context Analyzing the corporate and business unit goals and objectives and blockages to achieving these are critical elements of a strategic AI blueprint, as they set the direction for where AI can be leveraged most effectively as an enabler to solve the challenges and meet the objectives. **It is important to clearly analyze what the organization can achieve through the use of AI, and how it aligns with the broader business strategy.**

For instance, a pharma company may have a clear goal where Ai can be leveraged to improve drug discovery and development processes by reducing time and costs, improving efficiency, and increasing success rates. By integrating the corporate or business unit goals and objectives and unmet needs, organizations can focus their efforts and investments on areas that provide the greatest value and help measure the success of their AI initiatives.

To illustrate the importance of setting clear goals, a study by McKinsey & Company found that companies with clear AI strategies and goals outperform those that do not. The study also found that clear goals and a strong business case are critical for obtaining buy-in from stakeholders, including employees, customers, and regulators.

Furthermore, a report by Accenture identified that companies that successfully implemented AI solutions had clear business objectives, which were linked to measurable metrics. They also had a strong understanding of the ROI and impact of AI solutions on their business processes.

> *By defining a clear strategy for AI implementation, pharmaceutical companies can ensure that their AI initiatives are focused on addressing the most important business challenges and opportunities.*

Understanding stakeholder unmet needs: Understanding stakeholder unmet needs is a crucial element of an AI blueprint. **It involves identifying the problems that stakeholders are facing and determining how AI can help address those problems. In the pharma industry, stakeholders could include patients, healthcare providers, regulators, and employees.** By understanding their unmet needs, pharma companies can create AI solutions that *solutions that clearly support or align with desired outcomes such as operational efficiency or better patient outcomes*, enhance operational efficiency, and meet regulatory requirements.

Understanding stakeholder unmet needs can help pharma companies identify new business opportunities and revenue streams. For example, by using AI to analyze patient data, pharma companies can identify new patient populations for their existing drugs or develop new drugs to target unmet medical needs.

Ecosystem analysis: Ecosystem analysis is an essential element of an AI blueprint, as it helps to identify the various stakeholders, and systems that may be impacted by the AI implementation. **It involves mapping out the different components of the ecosystem, such as suppliers, customers, competitors, regulators, and understanding their interactions and dependencies.** This analysis helps to identify potential roadblocks, risks, and opportunities and enables organizations to develop strategies for collaborating with stakeholders and managing potential conflicts.

Understanding stakeholder unmet needs can help pharma companies identify new business opportunities and revenue streams.

Business needs analysis: Business needs analysis is a critical element of an AI blueprint. **It involves a comprehensive review of the organization's business processes and priorities improvement areas, to identify areas where AI solutions can add the most value.** This analysis helps to ensure that AI initiatives are aligned with the overall business strategy and can deliver meaningful results.

For instance, in the pharmaceutical industry, AI-powered solutions can help in drug discovery, clinical trial optimization, personalized medicine, supply chain, medical affairs, regulatory, PV, market access, and right through to sales and marketing. A business needs analysis can identify areas where AI can improve these processes or drive innovation, and assist in solving unmet needs and pain points currently existing.

Assess strategic fit and evaluate against set criteria: Assessing strategic fit and evaluating potential AI initiatives against set criteria is a crucial element of developing an AI blueprint. This process ensures that the selected AI projects align with the overall strategic goals and objectives of the pharmaceutical company.

These criteria could include feasibility, scalability, likely impact, urgency, cost-benefit analysis, risks of implementation to name a few.

Why a Strategic Blueprint is Imperative for Successful Implementation - WhitePaper with comments.

HOW PHARMA CAN ENSURE AI IS EMPLOYED STRATEGICALLY

In today's rapidly evolving pharmaceutical landscape, harnessing the power of artificial intelligence (AI) is crucial for staying competitive. However, many organizations make the mistake of viewing AI as a plug-and-play solution with immediate returns, leading to fragmented implementation and limited success.

The strategic deployment of AI requires a holistic approach that encompasses technology, culture, and organizational alignment, and the best place to begin to ensure all aspects will ensure success is the creation of an AI strategic blueprint. We offer comprehensive support across various aspects to ensure a well-planned and executed integration and adoption of technology.

A strategic AI blueprint is the first step in planning the approach to leverage AI is a critical first step. The advantages of this are:

1. **The ability to have a blueprint that ensures success and allows the shifting from failed pilots to successful company-wide programs:** A common pitfall faced by pharma leaders is struggling to move from AI pilots to companywide programs. It is critical to align AI initiatives with broader organizational priorities, ensuring that the initiatives address not only isolated business issues but also the overarching challenges faced by the entire organization. Through the creation of a strategic AI blueprint, we facilitate the transition from pilot projects to comprehensive AI programs that deliver significant business impact.

The strategic deployment of AI requires a holistic approach that encompasses technology, culture, and organizational alignment, and the best place to begin to ensure all aspects will ensure success is the creation of an AI strategic blueprint.

2. **Anticipating and Overcoming Barriers to Change:** Each organization faces unique barriers to AI adoption, which may stem from cultural, structural, or process-related factors. A strategic AI blueprint assists pharma leaders in anticipating these barriers by conducting an understanding of the specific challenges that may hinder adoption.

3. **Budgeting:** To ensure the successful scaling of AI initiatives, organizations must assess whether there is a strong cost-benefit and if so, allocate sufficient resources for successful implementation. Companies that avoid a strategic blueprint often spend far more time and resources than they should due to a lack of upfront understanding and planning.

4. **Balancing Feasibility, Time Investment, and Value:** We advise pharma leaders to develop a portfolio of AI initiatives with varying time horizons, considering feasibility, time investment, and expected value. Organizations must prioritize initiatives based on a long-term view and the potential for value creation. By combining quick wins with longer-term projects, organizations can achieve a balance between immediate impact and sustained transformation. Starting with an AI strategic blueprint ensures that AI initiatives align with business objectives and deliver value across different time frames.

5. **Oversight and Execution:** Effective oversight and execution are critical for the successful deployment of AI.

Companies that avoid a strategic blueprint often spend far more time and resources than they should due to a lack of upfront understanding and planning.

CONCLUSION

The success of AI implementation in the pharmaceutical industry relies on the early development of a strategic AI blueprint in collaboration with AI experts. While AI is not a panacea, it can effectively address specific challenges and propel business growth. By prioritizing the right issues and aligning AI initiatives with strategic goals, organizations can harness the power of AI to enhance business health and achieve success.

Our team at Eularis specializes in designing tailored strategic AI blueprints that align all AI initiatives with an organization's strategic objectives, resulting in remarkable progress. Through a comprehensive analysis of company strategies, customer needs, and the broader ecosystem, we identify areas where AI can make a significant impact. We assess core AI requirements, evaluate the compatibility of AI projects with the company's overall strategy, and deliver a strategic AI blueprint document that serves as a roadmap for success. With Eularis, your pharmaceutical or healthcare business can unlock the potential of AI and drive transformative growth.

ABOUT THE AUTHOR

Dr Andrée Bates

Dr. Andrée Bates is a pharmaceutical industry veteran with 30 years in the industry and 20 years working specifically in pharma AI. She brings blended expertise in Artificial Intelligence (AI), Pharmaceuticals, and Strategy. Dr. Bates has led Artificial Intelligence powered projects for numerous top-tier pharmaceutical companies in diverse areas such as clinical trials and R&D, market access, regulatory, medical affairs, and sales and marketing. These have all resulted in measurable growth in revenue, profit, and market share for her clients. Having worked in the pharmaceutical industry since 1993, and AI in Pharma since 2003, she has a detailed understanding of the pharmaceutical environment and how AI can be leveraged compliantly and effectively. She has authored many articles in peer-reviewed journals and industry reports. She has also been a guest lecturer on Healthcare Innovation and AI in multiple university MBA programs: INSEAD Business School (Fontainebleau), the Erivan K Haub School of Business at St Joseph's University (Pennsylvania), Fordham University (New York) Global Healthcare Innovation Management postgraduate program, and Bayes Business School (Formerly Cass Business School – The University of London), and she lectures on AI for Boards at Henley Business School at the University of Reading, as well being a guest speaker in numerous internal pharmaceutical company meetings and international conferences in UK, USA, Latin America, Canada, France, Germany, Spain, Hungry, Poland, Japan, China, Singapore, and Australia.

About Eularis

Eularis exist to help biopharma and healthcare commercial teams who want to weave FutureTech like Artificial Intelligence (AI) and Machine Learning (ML) and Virtual Reality (VR) and Augmented Reality (AR) and Internet of Things (IOT) to solve their challenges and deliver unprecedented measurable results.

The Eularis team of experts have extensive qualifications combined with many years of real-world experience in both biopharma and AI companies. The mix of qualifications (MD, PhD, MBA, M. Sc., M Engineer.) along with prior experience in executive-level positions in top 20 pharmaceutical companies ensures our clients have the right strategic and tactical questions solved and planned with cutting edge technology and AI. You have access to Pharma AI Futurists, Pharma Board level team, and AI Strategists, and Data Scientists and Big Data Engineers and Developers to ensure you are playing at the top of your game.

Every project is unique and begin by developing a deep understanding of your strategic needs and your data. Then, we plan the right approach to meet your strategic needs and transform your performance.

Learn more
eularis.com

ABOUT THE AUTHOR

Dr Andrée Bates

Dr. Andrée Bates is a pharmaceutical industry veteran with 30 years in the industry and 20 years working specifically in pharma AI. She brings blended expertise in Artificial Intelligence (AI), Pharmaceuticals, and Strategy. Dr. Bates has led Artificial Intelligence powered projects for numerous top-tier pharmaceutical companies in diverse areas such as clinical trials and R&D, market access, regulatory, medical affairs, and sales and marketing. These have all resulted in measurable growth in revenue, profit, and market share for her clients. Having worked in the pharmaceutical industry since 1993, and AI in Pharma since 2003, she has a detailed understanding of the pharmaceutical environment and how AI can be leveraged compliantly and effectively. She has authored many articles in peer-reviewed journals and industry reports. She has also been a guest lecturer on Healthcare Innovation and AI in multiple university MBA programs: INSEAD Business School (Fontainebleau), the Erivan K Haub School of Business at St Joseph's University (Pennsylvania), Fordham University (New York) Global Healthcare Innovation Management postgraduate program, and Bayes Business School (Formerly Cass Business School – The University of London), and she lectures on AI for Boards at Henley Business School at the University of Reading, as well being a guest speaker in numerous internal pharmaceutical company meetings and international conferences in UK, USA, Latin America, Canada, France, Germany, Spain, Hungry, Poland, Japan, China, Singapore, and Australia.

About Eularis

Eularis exist to help biopharma and healthcare commercial teams who want to weave FutureTech like Artificial Intelligence (AI) and Machine Learning (ML) and Virtual Reality (VR) and Augmented Reality (AR) and Internet of Things (IOT) to solve their challenges and deliver unprecedented measurable results.

The Eularis team of experts have extensive qualifications combined with many years of real-world experience in both biopharma and AI companies. The mix of qualifications (MD, PhD, MBA, M. Sc., M Engineer.) along with prior experience in executive-level positions in top 20 pharmaceutical companies ensures our clients have the right strategic and tactical questions solved and planned with cutting edge technology and AI. You have access to Pharma AI Futurists, Pharma Board level team, and AI Strategists, and Data Scientists and Big Data Engineers and Developers to ensure you are playing at the top of your game.

Every project is unique and begin by developing a deep understanding of your strategic needs and your data. Then, we plan the right approach to meet your strategic needs and transform your performance.

Learn more
eularis.com

TRY ONE OF OUR CORE SERVICES

1 AI STRATEGIC BLUEPRINT

Give us your most difficult challenges to solve with AI and FutureTech!

The problem of poor AI impact comes down to a lack of strategy and pre-strategy. We know AI is impressive, and we see the results all around us. So why do many pharma AI project never pass the pilot stage? There is a plethora of evidence as to why not having a strategic AI blueprint before you begin is problematic and leads to project failure. We create strategic AI blueprints to ensure all AI projects meet the company's strategic objectives and move the needle for maximum impact.

2 AI DEPLOYMENT BLUEPRINT

Ensuring the key foundational elements required for success in your AI FutureTech projects are in place.

In the pharma environment, we face unique challenges. Knowing where you want to go is one thing, but the trap many then fall into is ensuring that the key foundational elements are in place (e.g., finding the right data, getting through internal legal and compliance, buy vs build, tech planning SOW, choosing the optimal AI vendor etc.) so that you can execute quickly. Our deployment blueprint accelerates your ability to industrialise the opportunity effectively by taking care of all these foundation pieces enabling you to easily commercialize the most effective solutions rapidly and seamlessly.

3 AI MODEL IMPLEMENTATION & TECH BUILD

End-to-end solutions focused AI and tech implementation

Tech implementation from end-to-end including tech project planning, implementing security procedures, data discovery, data staging, data preparation, data AI modelling (with ML, NLP, Generative AI etc) model evaluation, UI/UX creation, integration services, software integration and cloud services, perform testing and quality controls and launch.

Contact us

Connect with Us